Senti Biosciences Inc-A 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedMarch31,2025or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period from ___to___Commission File Number001-40440 Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 86-2437900 (I.R.S. Employer Identification Number) (State or other jurisdiction of incorporation or organization) 2 Corporate Drive, First FloorSouth San Francisco,CA94080 (Address of principal executive offices and zip code)(650)239-2030 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common stock, par value $0.0001 pershare TheNasdaqCapital Market SNTI Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of April30, 2025 there were26,081,139shares of the registrant’s common stock, par value $0.0001 per share, issued andoutstanding. SENTI BIOSCIENCES, INC. TABLE OF CONTENTS Item 1.FINANCIAL STATEMENTS (UNAUDITED)1Condensed Consolidated Balance Sheets1Condensed ConsolidatedStatements of Operationsand Comprehensive Loss2Condensed Consolidated Statements of Stockholders’ Equity3Condensed Consolidated Statements of Cash Flows4Notes to Condensed Consolidated Financial Statements5Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS21Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK32Item 4.CONTROLS AND PROCEDURES33 PART II - OTHER INFORMATIONItem 1.LEGAL PROCEEDINGS35Item 1A.RISK FACTORS35Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS110Item 3.DEFAULTS UPON SENIOR SECURITIES110Item 4.MINE SAFETY DISCLOSURES110Item 5.OTHER INFORMATION110Item 6.EXHIBITS111 SIGNATURES SENTI BIOSCIENCES, INC.Condensed Consolidated Balance Sheets(In thousands, except share and per share amounts)(Unaudited) SENTI BIOSCIENCES, INC.Condensed Consolidated Statements of Operations and Comprehensive Loss(In thousands, except share and per share amounts)(Unaudited) SENTI BIOSCIENCES, INC.Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity(In thousands, except share data)(Unaudited) The accompanying notes are an integral part of these condensed consolidated financial statements. SENTI BIOSCIENCES, INC.Condensed Consolidated Statements of Cash Flows(In thousands)(Unaudited) SENTI BIOSCIENCES, INC. Notes to Condensed Consolidated Financial Statements(Unaudited) Note 1.Organization and Description of Business Senti Biosciences, Inc. and its subsidiaries (the “Company” or “Senti”), is a clinical stage biotechnology company developingnext-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurablediseases. Senti’s mission is to create a new generation of smarter therapies that can outsmart complex diseases using novel andunprecedented approaches. Senti has built a synthetic biology platform that enables it to program next-generation cell and genetherapies with gene circuits. These gene circuits, which are created from novel and proprietary combinations of DNA sequences,reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. The Company isheadquartered in South San Francisco, California. Liquidity and Going Concern These condensed consolidated financial statements have been prepared in accordance with generally accepted accountingprinciples in the